Anti-B4GT1/ B4GALT1/ B4GAL-T1 monoclonal antibody
Anti-B4GT1/ B4GALT1/ B4GAL-T1 antibody for FACS & in-vivo assay
Go to B4GALT1/B4GALT1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP0129-Ab-1/ GM-Tg-hg-MP0129-Ab-2 | Anti-Human B4GALT1 monoclonal antibody | Human |
GM-Tg-rg-MP0129-Ab-1/ GM-Tg-rg-MP0129-Ab-2 | Anti-Rat B4GALT1 monoclonal antibody | Rat |
GM-Tg-mg-MP0129-Ab-1/ GM-Tg-mg-MP0129-Ab-2 | Anti-Mouse B4GALT1 monoclonal antibody | Mouse |
GM-Tg-cynog-MP0129-Ab-1/ GM-Tg-cynog-MP0129-Ab-2 | Anti-Cynomolgus/ Rhesus macaque B4GALT1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP0129-Ab-1/ GM-Tg-felg-MP0129-Ab-2 | Anti-Feline B4GALT1 monoclonal antibody | Feline |
GM-Tg-cang-MP0129-Ab-1/ GM-Tg-cang-MP0129-Ab-2 | Anti-Canine B4GALT1 monoclonal antibody | Canine |
GM-Tg-bovg-MP0129-Ab-1/ GM-Tg-bovg-MP0129-Ab-2 | Anti-Bovine B4GALT1 monoclonal antibody | Bovine |
GM-Tg-equg-MP0129-Ab-1/ GM-Tg-equg-MP0129-Ab-2 | Anti-Equine B4GALT1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP0129-Ab-1/ GM-Tg-hg-MP0129-Ab-2; GM-Tg-rg-MP0129-Ab-1/ GM-Tg-rg-MP0129-Ab-2; GM-Tg-mg-MP0129-Ab-1/ GM-Tg-mg-MP0129-Ab-2; GM-Tg-cynog-MP0129-Ab-1/ GM-Tg-cynog-MP0129-Ab-2; GM-Tg-felg-MP0129-Ab-1/ GM-Tg-felg-MP0129-Ab-2; GM-Tg-cang-MP0129-Ab-1/ GM-Tg-cang-MP0129-Ab-2; GM-Tg-bovg-MP0129-Ab-1/ GM-Tg-bovg-MP0129-Ab-2; GM-Tg-equg-MP0129-Ab-1/ GM-Tg-equg-MP0129-Ab-2 |
Products Name | Anti-B4GALT1 monoclonal antibody |
Format | mab |
Target Name | B4GALT1 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-B4GALT1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species B4GT1/ B4GALT1/ B4GAL-T1 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | vGMLP002366 | 0 B4GALT1 Lentivirus particle |
ORF Viral Vector | pGMLP002366 | human B4GALT1 Lentivirus plasmid |
ORF Viral Vector | pGMLPm002325 | mouse B4galt1 Lentivirus plasmid |
ORF Viral Vector | vGMLPm002325 | mouse B4galt1 Lentivirus particle |
Target information
Target ID | GM-MP0129 |
Target Name | B4GALT1 |
Gene ID | 2683,14595,24390,703541,481579,101100927,281781,100068209 |
Gene Symbol and Synonyms | 4-GalT,4-GalT1,B-1,B4GAL-T1,B4GALT1,beta-1,beta4Gal-T1,CDG2D,CLDLFIB,GalT,Ggtb,GGTB2,GT1,GTB |
Uniprot Accession | P15291,P80225,P08037 |
Uniprot Entry Name | B4GT1_HUMAN,B4GT1_RAT,B4GT1_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000086062 |
Target Classification | N/A |
The target: B4GALT1, gene name: B4GALT1, also named as B4GAL-T1, CDG2D, GGTB2, GT1, GTB, beta4Gal-T1. This gene is one of seven beta-1,4-galactosyltransferase (beta4GalT) genes. They encode type II membrane-bound glycoproteins that appear to have exclusive specificity for the donor substrate UDP-galactose; all transfer galactose in a beta1,4 linkage to similar acceptor sugars: GlcNAc, Glc, and Xyl. Each beta4GalT has a distinct function in the biosynthesis of different glycoconjugates and saccharide structures. As type II membrane proteins, they have an N-terminal hydrophobic signal sequence that directs the protein to the Golgi apparatus and which then remains uncleaved to function as a transmembrane anchor. By sequence similarity, the beta4GalTs form four groups: beta4GalT1 and beta4GalT2, beta4GalT3 and beta4GalT4, beta4GalT5 and beta4GalT6, and beta4GalT7. This gene is unique among the beta4GalT genes because it encodes an enzyme that participates both in glycoconjugate and lactose biosynthesis. For the first activity, the enzyme adds galactose to N-acetylglucosamine residues that are either monosaccharides or the nonreducing ends of glycoprotein carbohydrate chains. The second activity is restricted to lactating mammary tissues where the enzyme forms a heterodimer with alpha-lactalbumin to catalyze UDP-galactose + D-glucose <=> UDP + lactose. The two enzymatic forms result from alternate transcription initiation sites and post-translational processing. Two transcripts, which differ only at the 5' end, with approximate lengths of 4.1 kb and 3.9 kb encode the same protein. The longer transcript encodes the type II membrane-bound, trans-Golgi resident protein involved in glycoconjugate biosynthesis. The shorter transcript encodes a protein which is cleaved to form the soluble lactose synthase. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.